Jounce Therapeutics - 48 Year Dividend History | JNCE
Historical dividend payout and yield for Jounce Therapeutics (JNCE) since 1971. The current TTM dividend payout for Jounce Therapeutics (JNCE) as of October 15, 2019 is $0.00. The current dividend yield for Jounce Therapeutics as of October 15, 2019 is 0.00%.
||Medical - Drug Manufacturing
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.